Results 1 to 10 of about 1,978 (184)

Adherence to the Dapivirine Vaginal Ring Among Cisgender Women in Africa: Protocol for a Systematic Review and Meta‐Analysis [PDF]

Health Science Reports
Background and Aims Despite the availability of HIV preventive measures, new HIV infections are still on the rise. The Dapivirine Vaginal Ring (DVR) is a silicone circular ring that continuously distributes 25 mg of Dapivirine into a woman's vagina for ...
Roseline Dzekem Dine, Giulia Muraca, Behnam Sadeghirad, Lawrence Mbuagbaw   +3 more
doaj   +3 more sources

PrEP choice in the real world: Results of a prospective cohort study describing uptake and use patterns of oral PrEP and the dapivirine vaginal ring among women in sub‐Saharan Africa [PDF]

Journal of the International AIDS Society
Introduction HIV incidence remains high among women in Africa, especially adolescent girls and young women (AGYW), despite existing oral pre‐exposure prophylaxis (PrEP) programmes.
Virginia A. Fonner, Elizabeth Irungu, Mark Conlon, Carolyne A. Akello, Emily Gwavava, Kevin K'Orimba, Nicolette P. Naidoo, Patriciah Jeckonia, Imelda Mahaka, Saiqa Mullick, Mamatli Chabela, Roisin Drysdale, Jacqueline Kabongo, Millicent Kiruki, Ivan Segawa, Munyaradzi Dobbie, Nthuseng Marake, Peter Mudiope, Hasina Subedar, Rose Wafula, Andrew Kazibwe, Jason Reed, Katharine Kripke, Douglas Taylor, Mu‐Tien Lee, Glory Chidumwa, Adatia Chivafa, Ramatsoai Soothoane, Margaret Eichleay, Ashley Mayo, Courtney McGuire, Tara McClure, Tatenda Yemeke, Kristine Torjesen, the CATALYST study team   +34 more
doaj   +3 more sources

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. [PDF]

PLoS ONE, 2016
BackgroundThis was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women.ObjectivesThe trial assessed and compared the safety, acceptability and adherence to ...
Annalene Nel, Linda-Gail Bekker, Elizabeth Bukusi, Elizabeth Hellstrӧm, Philip Kotze, Philip Kotze, Cheryl Louw, Francis Martinson, Gileard Masenga, Elizabeth Montgomery, Nelisiwe Ndaba, Ariane van der Straten, Neliëtte van Niekerk, Cynthia Woodsong   +13 more
doaj   +6 more sources

“People have options”: a qualitative study of experiences and influences of PrEP choice among women in South Africa [PDF]

Journal of the International AIDS Society
Introduction Long‐acting injectable cabotegravir and dapivirine vaginal ring were recently introduced in South Africa through demonstration projects, providing additional HIV prevention options to oral pre‐exposure prophylaxis (PrEP). PrEP choice marks a
Siphokazi Dada, Faith Mary Musvipwa, Fatima Abegail Cholo, Melanie Pleaner, Alison Kutywayo, Vusile Butler, Catherine Elizabeth Martin, Saiqa Mullick   +7 more
doaj   +3 more sources

HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania [PDF]

AIDS Research and Therapy, 2021
Background HIV risk remains high among adolescent girls and young women (AGYW, ages 15–24) in Tanzania. Many AGYW experience stigma and provider bias at health facilities, deterring their use of HIV prevention services.
Julia Tubert, Laura Packel, Lauren A. Hunter, Rashid Mfaume, Prosper Njau, Angela A. Ramadhani, Jenny X. Liu, Sandra I. McCoy   +7 more
doaj   +2 more sources

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study [PDF]

BMC Public Health, 2021
Background Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study ...
Morgan Garcia, Ellen Luecke, Ashley J. Mayo, Rachel Scheckter, Patrick Ndase, Flavia Matovu Kiweewa, Doreen Kemigisha, Petina Musara, Leila E. Mansoor, Nishanta Singh, Kubashni Woeber, Neetha S. Morar, Nitesha Jeenarain, Zakir Gaffoor, Daniel K. Gondwe, Yvonne Makala, Llewellyn Fleurs, Krishnaveni Reddy, Thesla Palanee-Phillips, Jared M. Baeten, Ariane van der Straten, Lydia Soto-Torres, Kristine Torjesen   +22 more
doaj   +2 more sources

A mixed-method study of feasibility and acceptability of the Dapivirine vaginal ring among adolescent girls and young women (AGYW) in selected Zimbabwean districts. [PDF]

PLOS Global Public Health
The Dapivirine vaginal ring (DPV-VR) is an intravaginal silicone ring that delivers an antiretroviral drug (Dapivirine) directly to vaginal tissues for 28 days.
Noah Taruberekera, Malvern Munjoma, Owen Mugurungi, Getrude Ncube, Miriam Mutseta, Munyaradzi Dhodho, Hanul Choi, Jabulani Mavudze, Tafara Moga, Blessing Mutede   +9 more
doaj   +3 more sources

Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development. [PDF]

PLoS ONE
End-user feedback early in product development is important for optimizing multipurpose prevention technologies for HIV and pregnancy prevention. We evaluated the acceptability of the 90-day dapivirine levonorgestrel ring (DPV-LNG ring) used for 14 days ...
Barbara A Friedland, Holly Gundacker, Sharon L Achilles, Beatrice A Chen, Craig Hoesley, Barbra A Richardson, Clifton W Kelly, Jeanna Piper, Sherri Johnson, Brid Devlin, John Steytler, Kyle Kleinbeck, Bindi Dangi, Chantél Friend, Mei Song, Barbara Mensch, Ariane van der Straten, Cindy Jacobson, Craig W Hendrix, Jill Brown, Diana Blithe, Sharon L Hiller, MTN-030/IPM 041 and MTN-044/IPM 053/CCN019 Protocol Teams for the Microbicide Trials Network and the Contraceptive Clinical Trials Network   +22 more
doaj   +3 more sources

Estimating the cost of and willingness to pay for providing the dapivirine ring for HIV prevention in Kenya [PDF]

BMC Public Health
Background As Kenya prepared to introduce the PrEP ring (a long-acting product used by women for HIV prevention), the need to understand the resources required became increasingly important.
Peter Stegman, Steven Forsythe, Urbanus Kioko, Millicent Kiruki, Patriciah Jeckonia, Martha Larson, Delivette Castor, Guy Mahiane, Maryline Mireku, Mike Ekisa, Kristine Torjesen, Mary Mugambi, Daniel Were, Katharine Kripke   +13 more
doaj   +2 more sources

Exploring pregnant women’s experiences with dapivirine vaginal ring insertion during the MTN-042/DELIVER study in Uganda: a description of secondary data [PDF]

Therapeutic Advances in Infectious Disease
Background: Involving pregnant women in HIV prevention trials is key to ensuring that they benefit from efficacious products. MTN-042/DELIVER was a phase IIIb, open-label, multi-site, randomized safety study, the first of its kind to enroll HIV-negative ...
Joselyne Nansimbe, Brenda Gati Mirembe, Phionah Kibalama Ssemambo, Annette Miwanda Ssekasi, Rose Byogero, Justine Nalwoga, Clemensia Nakabiito   +6 more
doaj   +2 more sources